Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

28 Aug 2020 15:27

RNS Number : 5084X
Collagen Solutions PLC
28 August 2020
 

Collagen Solutions plc

(the "Company")

 

Director/PDMR Dealing

 

1. Vesting / exercise of Deferred Bonus Awards granted in October 2019

 

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that, on 28 August 2020, the executive director and other persons discharging managerial responsibility ("PDMRs") set out in the table below acquired ordinary shares of 1 pence each in the share capital of the Company ("Shares") pursuant to the vesting / exercise of awards originally granted under the Collagen Solutions plc Deferred Bonus Plan on 2 October 2019 (the "Awards"). No consideration was payable for these Shares.

 

Director/PDMR

Position

Number of Shares acquired on 28 August 2020

Jamal Rushdy

Chief Executive Officer

906,145

Lou Ruggiero

Chief Business Officer

806,559

Brad Selman

PDMR / VP Global Sales and Marketing

284,202

Chris Wattengel

PDMR / VP Global R&D

246,514

Kevin Darling

PDMR / VP Tissue Products

173,596

 

Notes:

1 A number of other individuals, including Hilary Spence, Chief Financial Officer, were also granted Awards under the Deferred Bonus Plan on 2 October 2019. Although these Awards (which are in the form of "nil-cost" options) have now vested, the relevant holders have not yet elected to exercise their rights and acquire their Shares.

 

The Shares required to satisfy the above vestings / exercises were transferred to the relevant individuals by the trustee of the Collagen Solutions plc Employee Benefit Trust (the "EBT"). As previously announced, these Shares were allotted to the EBT on 11 August 2020.

 

2. Total beneficial holdings in the Company

 

Following the above notifications, the total holdings of Shares of the relevant PDMRs are as follows:

 

Director/PDMR

Position

Total holding following this notification

Approximate % of the Company's issued share capital

Jamal Rushdy

Chief Executive Officer

1,906,145

0.43%

Lou Ruggiero

Chief Business Officer

806,559

0.18%

Brad Selman

PDMR / VP Global Sales and Marketing

284,202

0.06%

Chris Wattengel

PDMR / VP Global R&D

246,514

0.06%

Kevin Darling

PDMR / VP Tissue Products

173,596

0.04%

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

1. Jamal Rushdy

2. Lou Ruggiero

3. Brad Selman

4. Chris Wattengel

5. Kevin Darling

2

Reason for the notification

a)

Position/status

1. Chief Executive Officer

2. Chief Business Officer

3. PDMR / VP Global Sales and Marketing

4. PDMR / VP Global R&D

5. PDMR / VP Tissue Products

b)

Initial notification/ Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Collagen Solutions plc

b)

LEI

213800IFY1CVGRGETL95

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of 1p each ("Shares")

Identification code

ISIN Code: GB00B94T6Y14

b)

Nature of the transaction

Acquisition of Shares on the vesting / exercise of Awards originally granted on 2 October 2019 pursuant to the Collagen Solutions plc Deferred Bonus Plan

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

1.

nil

906,145

2.

nil

806,559

3.

nil

284,202

4.

nil

246,514

5.

nil

173,596

d)

Aggregated information

- Aggregated volume

- Price

1. N/A single transaction

2. N/A single transaction

3. N/A single transaction

4. N/A single transaction

5. N/A single transaction

e)

Date of the transaction

2020-08-28

f)

Place of the transaction

Outside a trading venue

 

Enquiries:

Collagen Solutions Plc

Jamal Rushdy, CEO

 

Hilary Spence, CFO

Via Walbrook

Cenkos Securities Plc (Nominated Adviser and Broker)

Giles Balleny (Corporate Finance)

Tel: 0207 397 8900

Stephen Keys

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKKFBBQBKDPFB
Date   Source Headline
10th Mar 20152:56 pmRNSDirector/PDMR Shareholding
10th Mar 20157:03 amRNSRegulatory Approvals for Collagen Solutions Client
10th Mar 20157:03 amRNSTrading Statement and Acquisition Update
9th Jan 20157:00 amRNSInvestor Presentation
7th Jan 20154:04 pmRNSHolding(s) in Company
7th Jan 20157:00 amRNSCEO Presents at OneMedForum
5th Jan 20157:00 amRNSContract signed with Globus Medical Inc.
22nd Dec 20147:00 amRNSNew contract to supply Desu Medical
17th Dec 201410:54 amRNSHolding(s) in Company
15th Dec 20147:00 amRNSContract signed with Kyeron
12th Dec 201410:50 amRNSHolding(s) in Company
10th Dec 20147:00 amRNSSouthern Lights Biomaterials Acquisition Completed
24th Nov 201411:48 amRNSGrant of Options
21st Nov 20147:30 amRNSSchedule 1 - Collagen Solutions Plc
21st Nov 20147:00 amRNSAcquisition
21st Nov 20147:00 amRNSChange of Adviser
21st Nov 20147:00 amRNSHalf Yearly Report
22nd Oct 201412:30 pmRNSHolding(s) in Company
17th Oct 20147:00 amRNSJellagen Collaboration
10th Sep 201412:23 pmRNSHolding(s) in Company
3rd Sep 20147:00 amRNSAppointment to Scientific Advisory Board
27th Aug 201411:52 amRNSResult of AGM
29th Jul 20143:19 pmRNSHolding(s) in Company
18th Jul 20147:00 amRNSPosting of Annual Report & Notice of AGM
10th Jul 20147:00 amRNSFinal Results
3rd Jul 20147:00 amRNSChange of Registered Office
10th Jun 20147:00 amRNSExclusive Licencing of Intellectual Property
19th May 20147:00 amRNSProfessor Robert Brown joins as Scientific Adviser
15th May 20147:00 amRNSExcellagen® enters new clinical trial
26th Mar 201410:48 amRNSHolding(s) in Company
3rd Mar 20147:00 amRNSAppointment of Director
27th Dec 201312:25 pmRNSDirector Shareholding
27th Dec 201311:58 amRNSResult of GM
17th Dec 201310:00 amRNSAnnouncement by Cardium Therapeutics
16th Dec 20139:03 amRNSSchedule 1 - Healthcare Investment Opportunities
10th Dec 20137:00 amRNSHalf Yearly Report
10th Dec 20137:00 amRNSProposed acquisition
19th Aug 201311:06 amRNSHolding(s) in Company
1st Aug 20131:43 pmRNSHolding(s) in Company
2nd May 201312:00 pmRNSHolding(s) in Company
22nd Apr 201312:19 pmRNSHolding(s) in Company
9th Apr 201310:57 amRNSHolding in Company
8th Apr 20135:41 pmRNSHolding(s) in Company
5th Apr 20137:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.